Targeting cancer cell CCR2 enhances synergistic immune surveillance in breast cancer

Fein, M. R., He, X. Y., Almeida, A. S., Pommier, A., Bruzas, E., Eberhardt, A., Wilkinson, J. E., dos Santos, C., Egeblad, M. (May 2018) Targeting cancer cell CCR2 enhances synergistic immune surveillance in breast cancer. Cancer Research, 78 (10 Sup). pp. 75-76. ISSN 0008-5472

URL: http://cancerres.aacrjournals.org/content/78/10_Su...
DOI: 10.1158/1538-7445.MOUSEMODELS17-B42

Abstract

High expression of the C-C chemokine receptor type 2 (CCR2) in tumor samples and serum correlates with poor prognosis in human breast cancer, which has sparked interest in targeting the CCR2 pathway for therapeutic benefit. Importantly, a human CCR2 inhibitor (PF-04136309) has been investigated in clinical trials, and is currently being studied in a phase 1b/2 trial for pancreatic cancer (NCT02732938). Previous studies have focused on the protumor effects of CCR2 signaling in inflammatory monocytes. However, CCR2 is also expressed in breast cancer cells, but its potential function in cancer cells is poorly understood. To determine the specific roles of CCR2 in cancer and host cells, respectively, we established an orthotopic breast cancer mouse model by injecting primary cancer cells from MMTV-PyMT; Ccr2+/+ or MMTV-PyMT; Ccr2-/- mice into the mammary glands of wide-type or Ccr2 null hosts. In this cancer model, deleting Ccr2 in host cells, including monocytes, did not alter tumor growth. However, when tumor cells had lost Ccr2, immune surveillance was much more efficient, with greater infiltration and expansion of cytotoxic CD8+ T cell lymphocytes (CTLs) that efficiently recognized and destroyed the cancer cells, resulting in significant inhibition of tumor growth. Consistently, the delayed tumor growth of Ccr2 null cancer cells was fully reversed when these same cancer cells were transplanted into athymic (immunodeficient) mice. The reduced growth of tumors derived from Ccr2-/- cancer cells was associated with upregulation of IFN-γ response genes and genes involved in MHC class I presentation, as well as decreased expression of checkpoint inhibitor PD-L1 in cancer cells. Finally, greater infiltration of CD103+ dendritic cells (DCs) in Ccr2-/- tumor microenvironment also contributed to increased CTL function by cross presentation. Taken together, our results show that CCR2-expressing breast cancer cells orchestrated global changes in the infiltration of CTLs and DCs, leading to effective immune suppression. This suggests that CCR2 may be an immunotherapeutic target in breast cancer.

Item Type: Paper
Additional Information: Meeting Abstract
Subjects: diseases & disorders > cancer > cancer types > breast cancer
organs, tissues, organelles, cell types and functions > cell types and functions > cell functions > immunity
Publication Type > Meeting Abstract
CSHL Authors:
Communities: CSHL labs > Dos Santos lab
CSHL labs > Egeblad lab
Watson School > Publications
Depositing User: Matt Covey
Date: May 2018
Date Deposited: 01 Jun 2018 16:21
Last Modified: 03 Jan 2019 16:19
URI: http://repository.cshl.edu/id/eprint/36711

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving